# Same-Day Treatment With Genvoya vs. EFV/TDF/3TC

> **NCT03405194** · NA · WITHDRAWN · sponsor: **Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic**

## Conditions studied

- HIV/AIDS

## Interventions

- **DRUG:** Elvitegravir, Cobicistat, TAF, FTC
- **DRUG:** Efavirenz, TDF, and 3TC

## Key facts

- **NCT ID:** NCT03405194
- **Lead sponsor:** Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-05-01
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Haiti gained access to dolutegravir as first-line ART, so we cancelled the study before any patient was enrolled (we didn't want SOC group to receive EFV)
- **Last updated:** 2020-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03405194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03405194, "Same-Day Treatment With Genvoya vs. EFV/TDF/3TC". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03405194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*